
CATX Stock Forecast & Price Target
CATX Analyst Ratings
Bulls say
Perspective Therapeutics is a clinical-stage biopharmaceutical company with a vertically integrated, end-to-end 212Pb platform that has a structural advantage in its patented chelation technology and a regional manufacturing network designed to address industry competition and supply constraints. Clinical data has shown a potent alpha emission with minimal toxicity and deepening tumor reductions over time for its VMT-α-NET program, providing a favorable outlook for its three clinical-stage programs and upcoming data catalysts in 2026. The evolving NET treatment paradigm and increasing potential for earlier-line use make Perspective Therapeutics a differentiated frontrunner in the targeted alpha therapy space.
Bears say
Perspective Therapeutics is facing key risks in its pipeline programs, particularly with the delay in FDA approval for PSV359 and VMT01. The company also has a high valuation based on a sum-of-parts analysis, which could be concerning given the potential delays and uncertainties in their pipeline. Additionally, there is competition in the radiopharmaceutical market, which may limit the potential market for their targeted alpha-particle therapies.
This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares